[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
May 11, 1984

Successful Immunization of Infants With and Without Maternal Antibody by Aerosolized Measles Vaccine: II. Vaccine Comparisons and Evidence for Multiple Antibody Response

Author Affiliations

From the Sistema para El Desarrollo Integral de la Familia de Nuevo León, Universidad Autonoma de Nuevo León, Monterrey, Mexico (Dr Flores Arechiga); Dirrecion General de Epidemiologia, Secretaria de Salubridad y Asistencia, Mexico, DF (Dr Fernández de Castro); Division of Virology, Office of Biologics, Food and Drug Administration, Public Health Service (Dr Albrecht); and Infectious Diseases Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health (Drs Sever and Shekarchi) Bethesda, Md.; Dr Sabin, an emeritus professor of the University of Cincinnati (1971) and of the Medical University of South Carolina (1982), is currently a visiting professor in the Department of Microbiology, Georgetown University School of Medicine and Dentistry, Washington, DC.; Dr Flores Arechiga is now with Secretaria de Salubridad y Asistencia, Servicios Coordinados de Salud Publica en el Estado de Nuevo León, Monterrey, Mexico.

JAMA. 1984;251(18):2363-2371. doi:10.1001/jama.1984.03340420029022

In 4- and 5-month-old infants in whom the undiluted chick embryo fibroblast (CEF) Schwarz strain measles vaccine had a poor immunogenic effect, there was an increase in immunogenicity when the high sugar concentration was diminished without reference to added albumin. The human diploid cell (HDC) measles vaccine was still superior in this age group even in a lower concentration of the Ikić, Edmonston-Zagreb strain of virus. More aerosolized, HDC Ikić strain virus was required for high seroconversion rates in 4- and 5-month-old infants who had higher titers of prevaccination plaque-neutralizing (PN) antibodies. Some of these infants had a delayed immune response that was absent at six weeks but present at three months after vaccination. The data provided evidence that the PN and enzyme-linked immunosorbent assay techniques measured different antibodies that develop and persist in different ways in 4- to 5-month-old infants. The HDC lyophilized measles vaccine yielded unexpectedly high seroconversion rates after subcutaneous injection of 5,000 plaque-forming units (PFUs) in 4-, 5-, and 6-month-old infants: 69% 89%, and 100%, respectively, at 14 weeks. In 12- to 23-month-old infants there was seroconversion of 92% and 100% at six weeks after inhalation of an estimated 175 PFUs of the CEF vaccine and 375 PFUs of the HDC vaccine, respectively. Within six weeks after vaccination, the PN antibody titers were significantly higher with the CEF vaccine (geometric mean titer of 2,275) than with the HDC vaccine (geometric mean titer of 343).

(JAMA 1984;251:2363-2371)

Sabin AB, Flores Arechiga A, Fernández de Castro J, et al:  Successful immunization of children with and without maternal antibody by aerosolized measles vaccine: I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines .  JAMA 1983; 249:2651-2662.Crossref
Ikić D, Juzbas̃ić M, Beck M, et al:  Attentuation and characterization of Edmonston-Zagreb measles virus .  Ann Immunol Hung 1972;16:175-181.
Albrecht P, Herrmann K, Burns GR:  Role of virus strain in conventional and enhanced measles plaque neutralization test .  J Virol Methods 1981;3:251-260.Crossref
Smith FR, Curran AS, Raciti A, et al:  Reported measles in persons immunologically primed by prior vaccination .  J Pediatr 1982; 101:391-395.Crossref
Wilkins J, Wehrle PF:  Additional evidence against measles vaccine administration to infants less than 12 months of age: Altered immune response following active/passive immunization .  J Pediatr 1979;94:865-869.Crossref
Linnemann CC Jr, Dine MS, Roselle GA, et al:  Measles immunity after revaccination: Results in children vaccinated before 10 months of age .  Pediatrics 1982;69:332-335.
Shasby DM, Shope TC, Downs H, et al:  Epidemic measles in a highly vaccinated community .  N Engl J Med 1977;296:585-589.Crossref
Krugman S:  Further-attentuated measles vaccine: Characteristics and use .  Rev Infect Dis 1983;5:477-481.Crossref
Muhimbili Medical Centre, Dar-es-Salaam,  United Republic of Tanzania: Seroconversion after measles immunization .  WHO Weekly Epidemiol Rec 1981;56:234-237.
Medical Research Centre of Nairobi, Kenya:  The optimal age for measles immunization .  WHO Weekly Epidemiol Rec 1982;57:80-91.